– Q2 2021 Adjusted Total Revenue – $19.9 million –
– Q2 2021 Adjusted EBITDA – $7.4 million –
– Blexten Canadian Prescriptions Increased 26% Year-Over-Year –
– Cambia Canadian Prescriptions Increased 17% Year-Over-Year –
Miravo to Host Conference Call/Audio Webcast August 9th at 11:00 a.m. ET
Mississauga, Ontario, Canada – August 9, 2021 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and six months ended June 30, 2021. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2021, which are available on the Company’s website (www.miravohealthcare.com). All figures are in Canadian dollars, unless otherwise noted. Read full release here.